Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acelarin + Cisplatin in Advanced Biliary Tract Cancers
NCT02351765Phase 1Completed
- Sponsor
- The Christie
- Start
- Jan 2016
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pracinostat in biliary tract cancer (BTC), sponsored by The Christie. Primary endpoints: Safety profile of Acelarin in combination with Cisplatin and Maximum Tolerated Dose at 13 months. Started Jan 2016; status: completed.
02
Drugs
pracinostat
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT02351765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02351765.